目的 探討裸花紫珠顆粒聯(lián)合莫西沙星片治療慢性盆腔炎的臨床效果。方法 收集2020年4月—2023年4月東部戰(zhàn)區(qū)總醫(yī)院收治的75例慢性盆腔炎患者的臨床資料，根據(jù)用藥方案不同將75例慢性盆腔炎患者分為對(duì)照組（37例）和治療組（38例）。對(duì)照組口服莫西沙星片，0.4 g/次，1次/d。治療組在對(duì)照組基礎(chǔ)上開(kāi)水沖服裸花紫珠顆粒，3 g/次，3次/d。兩組持續(xù)治療2周。比較兩組臨床療效、臨床癥狀緩解時(shí)間、生活質(zhì)量、血清炎癥因子和復(fù)發(fā)情況。結(jié)果 對(duì)照組的總有效率為70.27%，治療組的總有效率為94.74%，組間比較差異有顯著性（P＜0.05）。治療組的白帶異常、下腹部疼痛、發(fā)熱緩解時(shí)間明顯短于對(duì)照組（P＜0.05）。治療后，兩組血清白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）、單核細(xì)胞趨化蛋白1（MCP-1）水平均降低（P＜0.05），治療組的血清IL-1β、TNF-α、MCP-1水平明顯低于對(duì)照組（P＜0.05）。隨訪后，兩組WHOQOL-BREF評(píng)分均顯著升高（P＜0.05），治療組的WHOQOL-BREF評(píng)分明顯高于對(duì)照組（P＜0.05）。治療組復(fù)發(fā)率低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。結(jié)論 慢性盆腔炎患者采用裸花紫珠顆粒聯(lián)合莫西沙星片治療可提高臨床療效，縮短臨床癥狀改善時(shí)間，提高患者生活質(zhì)量，降低患者炎癥因子水平和復(fù)發(fā)率。

Objective To explore the clinical effect of Luohuazizhu Granules combined with Moxifloxacin Tablets in treatment of chronic pelvic inflammatory disease. Methods Clinical data of 75 patients with chronic pelvic inflammatory disease admitted to Eastern Theater General Hospital from April 2020 to April 2023 were collected. Patients with chronic pelvic inflammatory disease were divided into control group (37 cases) and treatment group (38 cases) according to different medication regimens. The control group took Moxifloxacin Tablets orally, 0.4 g/time, once daily. The treatment group were po administered with Luohuazizhu Granules in boiling water on the basis of the control group, 3 g/time, 3 times daily. Two groups received continuous treatment for 2 weeks. The clinical efficacy, symptom relief time, quality of life, serum inflammatory factors, and recurrence were compared between two groups. ResultsThe total effective rate of the control group was 70.27%, while the total effective rate of the treatment group was 94.74%, and the difference between two groups was significant (P < 0.05). The relief time of abnormal vaginal discharge, lower abdominal pain, and fever in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the serum levels of IL-1β, TNF-α, and MCP-1 in two groups were decreased (P < 0.05), and the serum levels of IL-1β, TNF-α, and MCP-1 in the treatment group were significantly lower than those in the control group (P < 0.05). After follow-up, WHOQOL-BREF scores in two groups were significantly increased (P < 0.05), and WHOQOL-BREF scores in the treatment group were significantly higher than those in the control group (P < 0.05). The recurrence rate of the treatment group was lower than that of the control group, and the difference was statistically significant (P < 0.05). Conclusion The combination of Luohuazizhu Granules and Moxifloxacin Tablets in treatment of chronic pelvic inflammatory disease can improve clinical efficacy, shorten the time for clinical symptom improvement, improve patients' quality of life, reduce inflammation factor levels and recurrence rates

R984

東部戰(zhàn)區(qū)總醫(yī)院臨床診療新技術(shù)項(xiàng)目（22LCZLXJS30）